These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 15226490

  • 1. Short-duration therapy for respiratory tract infections.
    Goff DA.
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S19-23. PubMed ID: 15226490
    [Abstract] [Full Text] [Related]

  • 2. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R.
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [Abstract] [Full Text] [Related]

  • 5. Increased bacterial resistance: PROTEKT US--an update.
    Rybak MJ.
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S8-S13. PubMed ID: 15226488
    [Abstract] [Full Text] [Related]

  • 6. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
    Doern GV.
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.
    File TM.
    Clin Infect Dis; 2004 Sep 01; 39 Suppl 3():S159-64. PubMed ID: 15546111
    [Abstract] [Full Text] [Related]

  • 15. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
    File TM.
    Int J Antimicrob Agents; 2007 Dec 01; 30 Suppl 2():S131-4. PubMed ID: 18029151
    [Abstract] [Full Text] [Related]

  • 16. Rational use of antibiotics to treat respiratory tract infections.
    File TM, Hadley JA.
    Am J Manag Care; 2002 Aug 01; 8(8):713-27. PubMed ID: 12212759
    [Abstract] [Full Text] [Related]

  • 17. Clinical impact of antibiotic resistance in respiratory tract infections.
    Klugman KP.
    Int J Antimicrob Agents; 2007 Feb 01; 29 Suppl 1():S6-10. PubMed ID: 17307654
    [Abstract] [Full Text] [Related]

  • 18. How long should we treat community-acquired pneumonia?
    Scalera NM, File TM.
    Curr Opin Infect Dis; 2007 Apr 01; 20(2):177-81. PubMed ID: 17496577
    [Abstract] [Full Text] [Related]

  • 19. Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections.
    Nicolau DP.
    Am J Manag Care; 2004 Oct 01; 10(12 Suppl):S381-8. PubMed ID: 15603247
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.